US 9,789,062 B2Granted

Methods of treating arthritis

AssigneesTlc Biopharmaceuticals, Inc., Taiwan Liposome Co., Ltd.

InventorsKeelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin

Life of this patent

Estimating the term…

Abstract

The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Claims19

Dependent claims

A method of treating arthritis, comprising:

intraarticularly injecting a composition into a joint of a subject in need of treatment for arthritis, said composition comprising:
liposomes comprising 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), dipalmitoylphosphatidylglycerol (DOPG), and cholesterol, wherein the mole percent ratio of DOPC:DOPG:cholesterol is about 29.5 to 90 (DOPC):3 to 37.5 (DOPG):10 to 33 (cholesterol) based on the total amount of the phospholipids and cholesterol;
and
one or more therapeutic agents, wherein the therapeutic agent is not covalently bound to a phospholipid.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 14/411,530Filed 5 Jul 2013 · us provisional application
Priority: 5 Jul 2012
Published: US 2015/0174069 A125 Jun 2015
Granted: 17 Oct 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 31/405
Indoles, e.g. pindolol: indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Family

Application61/668,446Us provisional application · filed 5 Jul 2012
Application61/791,650Us provisional application · filed 15 Mar 2013
US 2015/0174069 A1Pre-grant publication · published 25 Jun 2015
US 9,789,062 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Facts

Application

14/411,530Filed 5 Jul 2013 · us provisional application

Priority

5 Jul 2012

Published

US 2015/0174069 A125 Jun 2015

Granted

17 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…
A61K 31/405
Indoles, e.g. pindolol: indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin